SaNOtize announced that it has closed a $24 million Series B funding round led by Horizons Ventures and OurCrowd with proceeds to go towards continued development of the company’s NONS nitric oxide nasal spray. The company initiated a Phase 3 trial of NONS for the treatment of COVID-19 in June 2021 and announced positive results from that study in July 2022. In August 2021, Glenmark announced that it had acquired the rights to NONS in India and other Asian countries.
According to SaNOtize, NONS is currently marketed as Enovid in Israel, Indonesia, and Bahrain and as VirX in Thailand, Hong Kong, and Singapore. Glenmark launched the nasal spray as FabiSpray in India in February 2022.
SaNOtize CEO Gilly Regev said, “We are thrilled to embark on these new partnerships, as they empower SaNOtize to accelerate its research program in various therapeutic fields and expand our Phase 3 NONS COVID-19 trial to additional countries. Our clinical and observational studies found NONS to be safe and effective at both treating and preventing COVID-19, even amid delta and omicron surges. We look forward to expanding our clinical research and working toward regulatory approval in the United States and Canada.”
Read the SaNOtize press release.
